
Genovis (Q3 Review) - A soft quarter ahead of a strong Q4

Redeye views Genovis' soft Q3 as a bump on the road ahead of a strong Q4. We share the CEO's view that the weakest period has passed, and while the stock trades in bear case territory, the growth outlook for 2026 remains positive.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Genovis (Q3 Review) - A soft quarter ahead of a strong Q4